Viganó J, Abbiati F, Alessiani M, Bonfichi M, Zonta S, Bardone M, Zitelli E, Cobianchi L, Doni M, Lovisetto F, Dominioni T, De Martino M, Lusona B, Arbustini E, Dionigi P
Department of Surgery, University of Pavia School of Medicine and I.R.C.C.S. Policlinico San Matteo Hospital, Piazzale Golgi 2, 27100 Pavia, Italy.
Transplant Proc. 2006 Jul-Aug;38(6):1818-20. doi: 10.1016/j.transproceed.2006.05.041.
As intestinal grafts require heavy immunosuppression, there are no reports of immunosuppression withdrawal after clinical small bowel transplantation. In this large-animal study, we investigated the occurrence of graft rejection in intestinal-transplanted pigs after withdrawal. Large-White unrelated piglets were transplanted and divided in three groups: group 1 (n = 5), intestinal transplantation (ITx) with no immunosuppression; group 2 (n = 7), Itx and 60 days of treatment with tacrolimus and mycophenolate mofetil; group 3 (n = 5), Itx and donor bone marrow infusion (DBMi) and 60 days of treatment with tacrolimus and mycophenolate mofetil. Follow-up time after withdrawal was 120 days. Group 1 pigs died of graft acute cellular rejection (ACR) after a median of 11 days. In group 2, two pigs died of ACR-related infection and another two of ACR within 90 days. The remaining three animals (43%) were sacrificed at day 180, and their grafts showed no signs of ACR. In group 3, two pigs died of ACR-related infection and one of graft versus host disease within 80 days; at day 180 the two surviving animals showed signs of chronic rejection in the allograft. This study demonstrates that total withdrawal after ITx is followed by sudden and lethal ACR (or ACR-related infection) in more than 50% of the recipients. When a tolerance-inducing strategy as DBMi is applied, lethal graft versus host disease may also occur. In group 3, the intestinal allograft, to which the recipients were partially tolerant, developed chronic rejection that was probably associated with a decline with time of donor-leukocytes chimerism, as recently demonstrated in rats.
由于肠道移植需要强效免疫抑制,目前尚无临床小肠移植后停用免疫抑制的报道。在这项大型动物研究中,我们调查了停用免疫抑制后肠道移植猪发生移植物排斥反应的情况。将大白猪无关仔猪进行移植,并分为三组:第1组(n = 5),进行肠道移植(ITx)且不使用免疫抑制;第2组(n = 7),ITx并使用他克莫司和霉酚酸酯治疗60天;第3组(n = 5),ITx并进行供体骨髓输注(DBMi)以及使用他克莫司和霉酚酸酯治疗60天。停用免疫抑制后的随访时间为120天。第1组猪在中位时间11天后死于移植物急性细胞排斥反应(ACR)。在第2组中,2头猪在90天内死于与ACR相关的感染,另外2头死于ACR。其余3只动物(43%)在第180天时被处死,其移植物未显示ACR迹象。在第3组中,2头猪在80天内死于与ACR相关的感染,1头死于移植物抗宿主病;在第180天时,2只存活动物的同种异体移植物出现慢性排斥反应迹象。这项研究表明,ITx后完全停用免疫抑制会导致超过50%的受者突然发生致命性ACR(或与ACR相关的感染)。当应用如DBMi这样的诱导耐受策略时,也可能发生致命的移植物抗宿主病。在第3组中,受者对其部分耐受的肠道同种异体移植物发生了慢性排斥反应,这可能与供体白细胞嵌合率随时间下降有关,正如最近在大鼠中所证实的那样。